Loading…
Reported covered position: Chief Oversight Counsel, Counsel, House Energy and Commerce Committee; Senior Counsel, Counsel, House Oversight and Government Reform Committee; Staff Assistant, House Judiciary Committee.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INCYTE CORPORATION via INCYTE CORPORATION
2026 · third_quarter · Q3
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Medication Affordability and Patent Integrity Act
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
2026 · second_quarter · Q2
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2026 · first_quarter · Q1
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · fourth_quarter · Q4
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · third_quarter · Q3
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · second_quarter · Q2
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · first_quarter · Q1
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · fourth_quarter · 4A
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · fourth_quarter · Q4
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE